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of SENCAR and C57BL/6 Mice to
Benzo(a)pyrene and the Interexperimental
Variability Over a Three-Year Period
by Stephen Nesnow,* Hinda Bergman,* and
Thomas J. Slagat
SENCAR and C57BL/6 mice were compared for their ability to produce tumors after benzo(a)pyrene
[B(a)PI initiation and 12-O-tetradecanoylphorbol-13-acetate (TPA) promotion. SENCAR mice initiated
with 101 ,ug/mouse B(a)P and promoted with TPA (2 ,g/mouse, twice weekly) produced large numbers of
papillomas, whereas C57BL/6 mice produced none after 26 weeks of promotion. Continued treatment of
the B(a)P-initiated C57BL/6 mice with TPA up to 52 weeks did not induce any papillomas nor did higher
doses of B(a)P. Application of increased doses of TPA (10 jig/mouse, twice weekly) to B(a)P-initiated
C57BL/6 mice (404 ,ug/mouse) for 50 weeks produced few papillomas. Substantial papilloma formation in
C57BL/6 mice was observed after weekly treatment with B(a)P (101 jg/mouse), with maximal production
occurringatweeks 39 to41 oftreatment. In contrast, SENCARmice treatedaccordingtothe sameprotocol
produced an equivalent response with maximal papilloma formation occurring 12 to 13 weeks earlier.
Therefore, C57BL/6 miceexposed toB(a)P arecapableofproducingpapillomasundercertain experimental
conditions.
The inter-experimental variability ofB(a)P-induced (50.5 jig/mouse) papilloma formation after 30 weeks
of TPA promotion (2 jig/mouse, twice weekly) was examined in SENCAR mice over a 37-month period.
Lowstatisticalvariationwasobservedinpapillomamultiplicity, papillomaincidence, orpapillomalatency.
Male and female SENCAR mice produced equal values in the three parameters: 4.4 + 1.6 papillomas/
mouse, 87% ± 10% of the mice bearing papillomas, and 9.6 ± 1.3 weeks (time at which 10%k of the mice
bore papillomas). The numbers of papillomas per mouse did not follow a Poisson distribution.
These data can serve as areference source for future comparisons ofmouse skin tumor initiation results
between SENCAR and other strains or stocks of mice and with other chemicals.
Introduction
The SENCAR mouse was originally developed by
Boutwell (1) by outbreeding Rockland STS mice with
Charles River CD-1 mice against a selective pressure
of 7,12-dimethylbenz(a)anthracene (DMBA) initation
and 12-0-tetradecanoylphorbol-13-acetate (TPA) pro-
motion for eight generations (2). Because of its dem-
onstrated increased sensitivity to the tumor-initiating
effects ofDMBA and benzo(a)pyrene [B(a)P] (3,4), this
mouse has been the subject of intensive investigations
using both complex mixtures and pure chemicals. We
have reported in a series of publications the tumor-
initiating, tumor-promoting, tumor-coinitiating, and
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complete carcinogenic properties of a wide variety of
complex mixtures, including gasoline exhausts, diesel
exhausts, coke oven and roofing tar emissions, and cig-
arette smoke condensate (5-8). In terms ofpure chem-
icals, many polycyclic aromatic hydrocarbons and their
derivatives have been examined using the SENCAR
mouse bioassay system (2-11). Also evaluated have
been respiratory carcinogenic metal salts (8), as well as
a series of known bladder, liver, and lung carcinogens
(12).
In our studies we had the opportunity to compare the
tumor-initiating and complete carcinogenic effects of
B(a)P in both SENCAR and C57BL/6 mice. In previous
papers we have reported that C57BL/6 mice are insen-
sitive to two-stage initiation-promotion with B(a)P and
TPA when the TPA was administered in 4-jig doses,
twiceweekly (13). Inthe studiesreportedhere, wehave
reconfirmed this phenomenon and have examined the
response ofC57BL/6 mice initiated with B(a)P and pro-NESNOW ET AL.
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FIGURE 1. Comparison of mouse skin tumor initiation induced by B(a)P in male and female SENCAR and C57BL/6 mice: (0) SENCAR;
(aJ) C57BL/6. Mice were initiated with B(a)P and promoted twice weekly with 2 jig of TPA and scored at week 26.
moted with an increased dose of TPA. Also examined
in C57BL/6 miceis thepapillomagenic response ofB(a)P
administered as a complete carcinogen.
We have also examined the interexperimental vari-
ation of papilloma response in SENCAR mice over a
37-month period. The results of these experiments are
presented and discussed, and these results may provide
a reference source for future comparisons with results
from other SENCAR mice experiments or for compar-
isons of responses with other mouse strains or stocks.
Materials and Methods
Seven- to nine-week-old SENCAR mice bred at Oak
Ridge National Laboratory or C57BL/6 mice (Charles
River Breeding Laboratory) were used. There were 80
animals (40 of each sex) per treatment group. Animals
were housed in plastic cages (10 per cage) under yellow
light with hardwood chip bedding, fed Purina chow and
water ad libitum, and maintained at 22-23°C with 10
changes of air per hour. All mice were shaved with
surgical clippers 2 days before the initialtreatment, and
only those mice in the resting phase of the hair cycle
were used.
Under the tumor-initiation protocol, B(a)P (Aldrich
Chemical Co., Milwaukee, WI) was applied as a single
topical treatment in 0.2 mL spectral quality acetone.
Beginning one week after treatment, a 2.0-,ug dose of
TPA (CCR, Eden Prairie, MN) in 0.2 mL acetone was
administered topically twice weekly, unless otherwise
Table 1. Mouse skin tumor initiation in C57BL/6 mice by B(a)P using higher doses of TPA.a
Number of mice survivingb Mice bearing papillomas, %b Papillomas/mouseb
Dose, ,ug/mouse Male Female Male Female Male Female
0 40 (39) 39 (38) 0 (0) 0 (0) 0 (0) 0 (0)
202 39 (37) 38 (35) 3 (22) 5 (11) 0.07 (0.35) 0.05 (0.11)
404 38 (36) 40 (37) 10 (6) 10 (14) 0.10 (0.05) 0.10 (0.13)
,Mice promoted with TPA 10 ,ug, twice weekly, 1 week after initiation.
bMice scored after 26 weeks and after 50 weeks ofpromotion. Values in parentheses are data after 50 weeks of promotion.
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FIGURE 2. Comparison of mouse skin complete carcinogenesis induced by B(a)P (101 pug/mouse administered weekly) in male and female
SENCAR and C57BL/6 mice: (0) SENCAR; (o) C57BL/6.
specified. Under the complete carcinogenesis protocol,
B(a)P was administered in 0.2 mL acetone weekly for
52 weeks.
Skin tumor formation was recorded weekly, and pap-
illomas greater than 2 mm in diameter and all carci-
nomas were included in the totals if they persisted for
one week or longer. The number of mice with tumors,
the number of mice surviving, and the total number of
tumors were determined and recorded weekly. At 6
months, the number ofpapillomas per surviving animal
was recorded for statistical purposes. The tumors were
histologically verified.
Results and Discussion
Comparison of SENCAR and C57BL/6
Mice
Using tumor initiation as the experimental protocol,
mice were initiated with B(a)P over a wide dose range:
0-101 ,ug/mouse for SENCAR mice and 0-404 pg/
mouse forC57BL/6 mice. Survival ofboth strains/stocks
was very high at week 26 with greater than 95% ofthe
mice surviving. Acetone-initiated/TPA-promoted con-
trol mice (males and females) gave the following re-
sponse: SENCAR, 0.07 papillomas/mouse, 7% of mice
bearing papillomas; C57BL/6, 0 papillomas/mouse, 0%
of mice bearing papillomas.
B(a)P elicited a strong dose-related effect in the pro-
duction of papillomas in SENCAR mice (Fig. 1),
whereas C57BL/6 mice exhibited no papillomas at any
dose tested at 26 weeks.
SENCAR mice were extremely sensitive to B(a)P
initiation/TPA promotion; 5.4 ,ug of B(a)P induced tu-
mors in 50% of the mice. The C57BL/6 mice were sub-
jected to additional treatment and were continuously
dosed with TPA (2 ,ug/twice weekly) to week52. Again,
these mice did not exhibit any papillomas (or carcino-
mas) at any dose, nor did the TPA control group. The
minimal survival at 52 weeks for the C57BL/6 mice was
88%. These results reconfirm our earlier findings ofthe
insensitivity of C57BL/6 mice to the tumor-promoting
effects of TPA (13).
To attempt to induce papillomas in C57BL/6 mice,
groups of 40 males and 40 females were initiated with
0, 202, and 404 jig/mouse of B(a)P and promoted with
10 jig of TPA twice weekly for 50 weeks. This dose of
TPA was five times that used in the previous experi-
ment(Fig. 1) and2.5timesthedosereportedbyReiners
et al. (13). Survival was high at both 26 and 50 weeks
of scoring with a minimum survival of 88% (Table 1).
Acetone-initiated/TPA-promoted mice again did not
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FIGURE 3. Interexperimental variation of skin papilloma incidence and multiplicity in B(a)P-initiated/TPA-promoted SENCAR mice. Male
and female mice were initiated with 50.5 ,ug/mouse of B(a)P and subsequently treated one week later with TPA (2 ,ug, twice weekly) for
30 weeks. Each data point represents an initial group of40 mice. Average survival was: male, 95%; female, 93%. Upper panel, male mice;
lower panel, female mice. Areas between dashed lines are 1 SD.
produce any papillomas or carcinomas. At 26 weeks, a
fewpapillomas wererecorded at404 ,ug/mouse ofB(a)P,
and this number did not increase at 50 weeks. The larg-
est number of papillomas was observed in the 202-,ug/
mouse group at 50 weeks: 0.35 papillomas/mouse, with
22% ofthe mice bearing papillomas. In previous studies
wehavedemonstrated that C57BL/6 mice initiatedwith
B(a)P are susceptible to the tumor-promoting proper-
ties of benzoyl peroxide (13). We conclude from the
studies reported here and from previous studies that
C57BL/6 mice are resistant to the tumor-promoting ef-
fects ofTPA rather than to the tumor-initiating effects
of B(a)P.
Papilloma formation in male and female SENCAR
and C57BL/6 mice induced by B(a)P under a complete
carcinogenesis protocol was compared (Fig. 2). Mice
were treated weekly with 101 ,ug/mouse ofB(a)P. Pap-
illomas were induced to about the same extent in both
strains/stocks in multiplicity (- two papillomas/mouse)
and incidence ( 90% of the mice bearing papillomas).
However, the temporal production of tumors was dra-
matically different. Maximal papilloma formation in
SENCAR mice occurred at 27 to 28 weeks, whereas in
C57BL/6 mice this peak occurred at 39 to 41 weeks, a
shift of 12 to 13 weeks.
In previously reported studies, SENCAR and
C57BL/6 mice were topically treated weekly with 12.5,
25.2, and 50.5 ,ug of B(a)P. Under these experimental
conditions, C57BL/6 mice produced few papillomas at
any time point, whereas SENCAR mice produced ap-
proximately one papilloma/mouse, with 40% of mice
bearing papillomas between weeks 30 and 40 of treat-
ment atthehighest dose (13). The studiesreported here
extend and augment the published investigations using
a two-fold higher dose ofB(a)P. Papilloma formation in
C57BL/6 mice is clearly evident at the higher dose of
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FIGURE 4. Interexperimental variation in skin papilloma latency in B(a)P-initiated/TPA-promoted SENCAR mice: (Upper panel) male mice;
(lower panel) female mice. See Fig. 2 legend for experimental details. Areas between dashed lines are ± 1 SD.
B(a)P and is equivalent in both SENCAR and C57BL/
6 mice. The reasons for the temporal shift in papilloma
fonnation between SENCAR and C57BL/6 mice are
unknown. Several explanations are possible, including
increased resistance ofC57BL/6 mice to B(a)P-induced
papillomagenesis orincreased cytotoxic effects ofB(a)P
on C57BL/6 mouse epidermis with subsequent produc-
tion of populations of cells resistant to the cytotoxic
effects of B(a)P.
Since both SENCAR and C57BL/6 mice produce
large numbers of carcinomas after weekly administra-
tion of B(a)P (12.5-50.5 ,ug/mouse/week) in previously
reported studies (14), the results reported here suggest
that production of carcinomas and papillomas may not
be directly related in C57BL/6 mice as suggested for
other mouse strains.
Interexperimental Variability of B(a)P-
Induced Papillomas
A series of 25 experiments with male and female
SENCAR mice treated with B(a)P (50.5 ,ug/mouse) and
promoted with TPA (2 R,g, twice weekly) were begun
over a 37-month period between April 1979 and May
1982. Intheseexperiments, the samesuppliersofB(a)P,
TPA, and acetone wereused, aswell asthe samebarrier
conditions and breeding protocols for producing SEN-
CAR mice.
Individual mice were scored at 30 weeks and the re-
sults of these studies presented in Figures 3-5. The
mean responses (+ SD) and ranges for papilloma inci-
dence for male and female mice were 87 + 10% (65%
to 100%) and 86 ± 10% (65 to 100%), respectively (Figs.
3 and 4). The coefficient of variation was the same for
both sexes at 12%. Papilloma multiplicity for male and
femalemice wasalsoequal, 4.4 + 1.6papillomas/mouse.
The coefficient ofvariation was 36%. The ranges ofpap-
illoma multiplicity for male and female mice were 1.6-
8.4 and 1.7-7.7, respectively. In terms ofmedian pap-
illoma incidence scores, male mice exhibited 89% mice
bearing papillomas, whereas females exhibited 87%.
Median papilloma multiplicity scores were 4.6 and 4.1
papillomas/mouse for male and female mice, respec-
tively.
Skin papilloma latency was determined by measuring
the time at which 10% ofthe mice bore papillomas (Fig.
4). The mean, standard deviation (SD), range, and me-
dian values in weeks were: 9.4, 1.1, 7-12, and 10 for
male mice and 9.8, 1.4, 7-13, and 10 for female mice.
Based on the three parameters-papilloma incidence,
papilloma multiplicity, and papilloma latency-equiv-
alent responses and variations were observed for male
and female SENCAR mice under these experimental
conditions.
Except for a few sporadic points, there seem to be
no consistent time-related effects with respect to the
production of mouse skin papillomas in SENCAR mice
over a 3-year period. The interexperimental variation
is relatively small in any ofthe three parameters mea-
sured and probably reflects the consistent breeding
scheme used in the production of SENCAR mice.
Skin papilloma distribution in B(a)P-initiated TPA-
promoted male and female SENCAR mice was deter-
mined from 15 experiments at 30 to 32 weeks of pro-
motion (Fig. 5). A non-Poisson distribution was ob-
served with manymice bearing0 to 6 papillomas/mouse
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and sporadic occurrences ofmice bearing more than 12
papillomas. One mouse had 26 papillomas. Drinkwater
and Klotz (15) have reported that mouse skin papilloma
multiplicitydatafollowanegativebinomialdistribution.
It is evident from these studies that statistical compar-
isons using normal or Poisson assumptions cannot be
applied to these data. In this regard, we have reported
on the use of a log probit analysis with nonzero back-
ground (16), which can be used to analyze mouse skin
papilloma data (5,6).
These data provide a useful tool for future compari-
sons of mouse skin tumor initiation data in SENCAR
or other strains or stocks of mice with B(a)P or with
other chemicals and can serve as a reference source for
this information.
The research described has been reviewed by the Health Effects
Research Laboratory, U.S. Environmental Protection Agency and
approved for publication. Approval does not signify that the contents
necessarily reflect the views and policies of the Agency nor does
mention of trade names or commercial products constitute endorse-
ment or recommendation for use.
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